Acknowledgments
TMP-IL, Anderson Cancer, Cancer
CANCER
V.K.M. was supported by the NIH/NCI under award number K12 CA088084 and the Cancer Prevention & Research Institute of Texas (CPRIT) under award number RP220416. This study was supported by the HPV Moonshot Program at MD Anderson and the NIH CCSG Award CA016672 (Institutional Tissue Bank [ITB] and Research Histology Core Laboratory [RHCL]), Adaptive Patient-Oriented Longitudinal Learning and Optimization (APOLLO) Moonshot Program, Strategic Alliances and the Translational Molecular Pathology-Immunoprofiling lab (TMP-IL) at the Department Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center. AstraZeneca provided the study drug and provided funding to MD Anderson Cancer Center for study conduct.